Normalization of CSF pTau measurement by Aβ(40) improves its performance as a biomarker of Alzheimer’s disease

BACKGROUND: Alzheimer’s disease (AD)-related tauopathy can be measured with CSF phosphorylated tau (pTau) and tau PET. We aim to investigate the associations between these measurements and their relative ability to predict subsequent disease progression. METHODS: In 219 cognitively unimpaired and 12...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Tengfei, Korman, Deniz, La Joie, Renaud, Shaw, Leslie M., Trojanowski, John Q., Jagust, William J., Landau, Susan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429887/
https://www.ncbi.nlm.nih.gov/pubmed/32799929
http://dx.doi.org/10.1186/s13195-020-00665-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429887/
https://www.ncbi.nlm.nih.gov/pubmed/32799929
http://dx.doi.org/10.1186/s13195-020-00665-8

Ejemplares similares